发布求助
文献互助 智能选刊 最新文献

Leukemia Research Reports最新文献

筛选
英文 中文
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP) Gemtuzumab Ozogamycin （GO）和3 + 7方案在适合新诊断的急性髓性白血病（AML）患者中的实际疗效和安全性“Pugliese Rete emat”（REP）的多中心回顾性研究
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100525
M. Dargenio , C. Buquicchio , D. Pastore , L. Aprile , L. Ciuffreda , G. Greco , M. Delia , V. Federico , MP. Fina , D. Seripa , R. Matera , G. Tarantini , A. Maggi , L. Melillo , V. Pavone , P. Musto , G. Specchia , N. Di Renzo
{"title":"Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)","authors":"M. Dargenio ,&nbsp;C. Buquicchio ,&nbsp;D. Pastore ,&nbsp;L. Aprile ,&nbsp;L. Ciuffreda ,&nbsp;G. Greco ,&nbsp;M. Delia ,&nbsp;V. Federico ,&nbsp;MP. Fina ,&nbsp;D. Seripa ,&nbsp;R. Matera ,&nbsp;G. Tarantini ,&nbsp;A. Maggi ,&nbsp;L. Melillo ,&nbsp;V. Pavone ,&nbsp;P. Musto ,&nbsp;G. Specchia ,&nbsp;N. Di Renzo","doi":"10.1016/j.lrr.2025.100525","DOIUrl":"10.1016/j.lrr.2025.100525","url":null,"abstract":"<div><div>Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with “3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside clinical trials. Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25–75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100525"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The synergistic effect of 2-deoxy-D-glucose and cytarabine on mitochondria of stem-like cells derived from KG1-a 2-脱氧-d -葡萄糖和阿糖胞苷对KG1-a源性干细胞线粒体的协同作用
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100537
Sona Rezaei , Mohammad Mohammadzadeh-Vardin , Keyvan Amirshahrokhi , Mojtaba Amani
{"title":"The synergistic effect of 2-deoxy-D-glucose and cytarabine on mitochondria of stem-like cells derived from KG1-a","authors":"Sona Rezaei ,&nbsp;Mohammad Mohammadzadeh-Vardin ,&nbsp;Keyvan Amirshahrokhi ,&nbsp;Mojtaba Amani","doi":"10.1016/j.lrr.2025.100537","DOIUrl":"10.1016/j.lrr.2025.100537","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) often relapses post-chemotherapy due to leukemia stem cells (LSCs), which rely on mitochondria for energy, ROS regulation, and apoptosis. Targeting mitochondrial pathways may overcome LSC resistance. This study evaluated Cytarabine (Ara-C), 2-Deoxy-d-Glucose (2-DG), and their combination on AML-derived KG1-a cells using MTT assays, showing reduced viability with combined treatment. The Magnetic sorting isolated CD34+ (stem-like) and CD34- cells. Flow cytometry revealed increased ROS and decreased mitochondrial membrane potential (MMP) in KG1-a and CD34+ cells with 2-DG and Ara-C, suggesting a promising strategy to target resistant LSCs in AML therapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100537"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy 在对酪氨酸激酶抑制剂治疗持续主要分子反应的CML患者中，费城染色体阴性AML的快速发展
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100536
Huan Liu , Yunxia Sun , Liangliang Li , Yurong Zhang , Yaxiong Zhou , Pengyun Zeng , Lingling Yue
{"title":"Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy","authors":"Huan Liu ,&nbsp;Yunxia Sun ,&nbsp;Liangliang Li ,&nbsp;Yurong Zhang ,&nbsp;Yaxiong Zhou ,&nbsp;Pengyun Zeng ,&nbsp;Lingling Yue","doi":"10.1016/j.lrr.2025.100536","DOIUrl":"10.1016/j.lrr.2025.100536","url":null,"abstract":"<div><div>The use of TKIs has significantly improved the prognosis of CML. However, a small subset of patients still experience poor outcomes. We present a rare case of Ph-AML following a diagnosis of CML. The patient achieved CCyR and MMR after 4 months of nilotinib therapy, with sustained deep remission for 3 years. Unexpectedly, the disease developed rapidly to AML. Further investigations revealed the emergence of CCA/Ph- and gene mutations. We retrospectively analyzed previous CML patients with <em>BCR::ABL1</em> and Ph-negative status in blast crisis from our database and conducted a comprehensive review of the relevant literature.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100536"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Le lymphome cutanée primitif diffus à grandes cellules B : à propos d’un cas Primary cutaneous diffuse large B-cell lymphoma: a case report 原发性皮肤弥漫性大B细胞淋巴瘤：病例报告
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100538
Mustapha Mechtoune , Fatima Zahra Lahlimi , Illias Tazi , Hanane Rais , Houda Jouihri , Mohammed el Fadli
{"title":"Le lymphome cutanée primitif diffus à grandes cellules B : à propos d’un cas Primary cutaneous diffuse large B-cell lymphoma: a case report","authors":"Mustapha Mechtoune ,&nbsp;Fatima Zahra Lahlimi ,&nbsp;Illias Tazi ,&nbsp;Hanane Rais ,&nbsp;Houda Jouihri ,&nbsp;Mohammed el Fadli","doi":"10.1016/j.lrr.2025.100538","DOIUrl":"10.1016/j.lrr.2025.100538","url":null,"abstract":"<div><div>The association of cutaneous B-cell lymphoma and dermatofibrosarcoma is exceptional. We report the case of a 44-year-old patient with a history of Darier-Ferrand dermatofibrosarcoma who presented with cutaneous B-cell lymphoma characterized by large atypical skin lesions with an aggressive course. The patient was treated with a combination of RCHOP-type chemotherapy and surgical treatment. We shed light on this very rare association whose prognosis depends on early diagnosis and adequate management.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100538"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia 阿西米尼和inotuzumab ozogamicin：一种治疗高度难治性ph阳性b细胞急性淋巴细胞白血病的新组合
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100546
Aneta Strumilowska , Katherine Devitt , Joanna Conant , Juli-Anne Gardner , Ashley Volaric , Neel Hegde , Diego Adrianzen-Herrera
{"title":"Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia","authors":"Aneta Strumilowska ,&nbsp;Katherine Devitt ,&nbsp;Joanna Conant ,&nbsp;Juli-Anne Gardner ,&nbsp;Ashley Volaric ,&nbsp;Neel Hegde ,&nbsp;Diego Adrianzen-Herrera","doi":"10.1016/j.lrr.2025.100546","DOIUrl":"10.1016/j.lrr.2025.100546","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100546"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype 浆细胞肿瘤向具有单核细胞特征的急性髓系白血病的反分化：基因型相同但表型不同的病例报告
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100504
Saja Asakrah , Kristin K. Deeb , Nikolaos Papadantonakis , George Deeb
{"title":"Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype","authors":"Saja Asakrah ,&nbsp;Kristin K. Deeb ,&nbsp;Nikolaos Papadantonakis ,&nbsp;George Deeb","doi":"10.1016/j.lrr.2025.100504","DOIUrl":"10.1016/j.lrr.2025.100504","url":null,"abstract":"<div><div>Myeloid malignancies following treatment for plasma cell neoplasms (PCN) are infrequent but is a serious complication, often exhibiting complex karyotype and <em>TP53</em> mutations. Plasma cell myeloma lineage switch to a myeloid malignancy with evident clonal relatedness is seldomly reported. Here, we report a unique case of acute myeloid leukemia with monocytic differentiation that shares clonal features with an antecedent plasma cell myeloma with t(4;14)(<em>FGFR3::IGH</em>). This phenomenon differs from therapy-related myeloid neoplasm arising from an unrelated clone and underscores the need to elucidate the role of mutations in pathways such as MAPK (e.g., <em>BRAF</em> and <em>KRAS</em>) into lineage plasticity.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100504"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia 未采取的道路：探索非移植选择在De Novo费城阳性急性髓性白血病
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100507
Mohamed I Sharif, Ahmad S. Alotaibi, Ruah Alyamany, Ali Alahmari, Hanan Alkhaldi, Ayman Saad, Mansour Alfayez
{"title":"The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia","authors":"Mohamed I Sharif,&nbsp;Ahmad S. Alotaibi,&nbsp;Ruah Alyamany,&nbsp;Ali Alahmari,&nbsp;Hanan Alkhaldi,&nbsp;Ayman Saad,&nbsp;Mansour Alfayez","doi":"10.1016/j.lrr.2025.100507","DOIUrl":"10.1016/j.lrr.2025.100507","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a heterogeneous disease with diverse molecular cytogenetic characteristics. Philadelphia-positive acute myeloid leukemia, a rare subtype of AML, is traditionally considered a high-risk, with the standard recommendation being an allogeneic hematopoietic cell transplant (HCT) in first remission. More recently, with better characterization and understanding of AML biology, novel therapies have been introduced. Drawing parallels from the advances seen in Philadelphia-positive acute lymphoblastic leukemia (ALL), the question arises whether potent tyrosine kinase inhibitors (TKI), such as ponatinib, in combination with AML-directed therapies, could be used in Philadelphia-positive AML, potentially eliminating the need for HCT in the first remission.</div><div>In this report, we review the literature on Philadelphia-positive AML, study a case where HCT was omitted, and explore potential signals that could support successful HCT omission.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100507"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency 急性髓性白血病：获得性分离因子VII缺乏的罕见原因
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100516
Zaineb Mlayah, Haifa Hafsa, Alaa Ghorbel, Nader Slama, Sara Boukhris, Mohamed-Adnene Laatiri
{"title":"Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency","authors":"Zaineb Mlayah,&nbsp;Haifa Hafsa,&nbsp;Alaa Ghorbel,&nbsp;Nader Slama,&nbsp;Sara Boukhris,&nbsp;Mohamed-Adnene Laatiri","doi":"10.1016/j.lrr.2025.100516","DOIUrl":"10.1016/j.lrr.2025.100516","url":null,"abstract":"<div><h3>Background</h3><div>Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.</div></div><div><h3>Case presentation</h3><div>A 38-year-old Arab male with AML was diagnosed at our Department of Clinical Hematology. The initial coagulation panel at admission revealed slightly low prothrombin ratio (PT) of 56 %, while the international normalized ratio (INR) and partial thromboplastin time (PTT) were within normal. Prothrombin complex coagulation factor dosing (PCCFD) confirmed an isolated reduction in the FVII in repeated samples, indicating an isolated deficiency. This patient did not present severe bleeding syndrome and had received conventional chemotherapy (cytarabine (Cytarabine)+ idarubicin). The evolution was marked by cytological remission (CR) with correction of coagulation disorders.</div></div><div><h3>Conclusion</h3><div>In conclusion, the intricate relationship between isolated aFVIID and AML remains mysterious. Researchers are essential to unravel the intricacies of this rare hematological condition. Further exploration into the molecular mechanisms, prognostic implications, and evolving treatment modalities is crucial to enhance the precision and efficacy of therapeutic interventions.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100516"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteasome inhibitors prevent tumor cell proliferation in HHV-8-unrelated PEL-like lymphoma 蛋白酶体抑制剂阻止hhv -8无关的pel样淋巴瘤的肿瘤细胞增殖。
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100497
Kiyotaka Kawauchi , Toshie Ogasawara
{"title":"Proteasome inhibitors prevent tumor cell proliferation in HHV-8-unrelated PEL-like lymphoma","authors":"Kiyotaka Kawauchi ,&nbsp;Toshie Ogasawara","doi":"10.1016/j.lrr.2024.100497","DOIUrl":"10.1016/j.lrr.2024.100497","url":null,"abstract":"<div><div>Primary effusion lymphoma (PEL)-like lymphoma is a rare variant of PEL that exhibits diverse clinical behaviors, ranging from mild to aggressive disease courses. The clinicopathological features and effective treatments for this type of lymphoma have not been well defined. We found that proteasome inhibitors were effective in inhibiting the growth and survival of OGU1 cells, which were derived from a patient with aggressive PEL-like lymphoma, highlighting the critical role of proteasome activity in the proliferation of PEL-like lymphoma cells. This suggests that proteasome inhibitors, such as bortezomib, could be promising therapeutic options for patients who respond poorly to conventional chemotherapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100497"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and prognostic relevance of RAF1 gene in acute myeloid leukemia 急性髓系白血病中RAF1基因的诊断和预后相关性
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100528
Seyedeh Kosar Rahimpour , Yasin Mirazimi , Seyedeh Zahra Shahrokhi , Mohammad Sayyadi , Maryam Kargar , Mohammad Rafiee
{"title":"Diagnostic and prognostic relevance of RAF1 gene in acute myeloid leukemia","authors":"Seyedeh Kosar Rahimpour ,&nbsp;Yasin Mirazimi ,&nbsp;Seyedeh Zahra Shahrokhi ,&nbsp;Mohammad Sayyadi ,&nbsp;Maryam Kargar ,&nbsp;Mohammad Rafiee","doi":"10.1016/j.lrr.2025.100528","DOIUrl":"10.1016/j.lrr.2025.100528","url":null,"abstract":"<div><div>Acute Myeloid Leukemia (AML) demands precise diagnostic and prognostic tools for accurate detection and personalized-treatment strategies. Using Real-Time PCR, we investigated the RAF1, miR-146 b-3p, and Circ-RPL15 network expression in AML. Because RAF1 is a crucial gene involved in various ways, it is considered a potential biomarker for prognosis and diagnosis. While no significant correlation was found within the network, RAF1 expression showed a marked difference between groups. ROC curve analysis for RAF1 demonstrated promising diagnostic performance, and our bioinformatics investigations supported its strong prognostic potential. Identifying such biomarkers can aid in developing better management based on patients' characteristics.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100528"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信